# A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients

> **NCT01588769** · PHASE1 · COMPLETED · sponsor: **CytoVac A/S** · enrollment: 23 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **BIOLOGICAL:** ALECSAT cell based immunotherapy

## Key facts

- **NCT ID:** NCT01588769
- **Lead sponsor:** CytoVac A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-11
- **Final completion:** 2013-04
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01588769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01588769, "A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01588769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*